Association of altered metabolic profiles and long non-coding RNAs expression with disease severity in breast cancer patients: analysis by 1H NMR spectroscopy and RT-q-PCR
Tóm tắt
Globally, one of the major causes of cancer related deaths in women is breast cancer. Although metabolic pattern is altered in cancer patients, robust metabolic biomarkers with a potential to improve the screening and disease monitoring are lacking. A complete metabolome profiling of breast cancer patients may lead to the identification of diagnostic/prognostic markers and potential targets. The aim of this study was to analyze the metabolic profile in the serum from 43 breast cancer patients and 13 healthy individuals. We used 1H NMR spectroscopy for the identification and quantification of metabolites. q-RT-PCR was used to examine the relative expression of lncRNAs. Metabolites such as amino acids, lipids, membrane metabolites, lipoproteins, and energy metabolites were observed in the serum from both patients and healthy individuals. Using unsupervised PCA, supervised PLS-DA, supervised OPLS-DA, and random forest classification, we observed that more than 25 metabolites were altered in the breast cancer patients. Metabolites with AUC value > 0.9 were selected for further analysis that revealed significant elevation of lactate, LPR and glycerol, while the level of glucose, succinate, and isobutyrate was reduced in breast cancer patients in comparison to healthy control. The level of these metabolites (except LPR) was altered in advanced-stage breast cancer patients in comparison to early-stage breast cancer patients. The altered metabolites were also associated with over 25 signaling pathways related to metabolism. Further, lncRNAs such as H19, MEG3 and GAS5 were dysregulated in the breast tumor tissue in comparison to normal adjacent tissue. The study provides insights into metabolic alteration in breast cancer patients. It also provides an avenue to examine the association of lncRNAs with metabolic patterns in patients.
Tài liệu tham khảo
Awasthee, N., Rai, V., Verma, S. S., Francis, K. S., Nair, M. S., & Gupta, S. C. (2018). Anti-cancer activities of Bharangin against breast cancer: Evidence for the role of NF-κB and lncRNAs. Biochimica et Biophysica Acta (BBA)-General Subjects, 1862, 2738–2749.
Bhandari, P. M., Thapa, K., Dhakal, S., Bhochhibhoya, S., Deuja, R., Acharya, P., & Mishra, S. R. (2016). Breast cancer literacy among higher secondary students: Results from a cross-sectional study in Western Nepal. BMC cancer, 16, 1–9.
Bonuccelli, G., Tsirigos, A., Whitaker-Menezes, D., Pavlides, S., Pestell, R. G., Chiavarina, B., Frank, P. G., Flomenberg, N., Howell, A., Martinez-Outschoorn, U. E., & Sotgia, F. (2010). Ketones and lactate “fuel” tumor growth and metastasis: Evidence that epithelial cancer cells use oxidative mitochondrial metabolism. Cell Cycle, 9, 3506–3514.
Cassim, S., & Pouyssegur, J. (2019). Tumor microenvironment: A metabolic player that shapes the immune response. International Journal of Molecular Sciences, 21, 157.
Chandra Gupta, S., & Nandan Tripathi, Y. (2017). Potential of long non-coding RNAs in cancer patients: From biomarkers to therapeutic targets. International Journal of Cancer, 140, 1955–1967.
Chen, Y., Zhang, R., Song, Y., He, J., Sun, J., Bai, J., An, Z., Dong, L., Zhan, Q., & Abliz, Z. (2009). RRLC-MS/MS-based metabonomics combined with in-depth analysis of metabolic correlation network: Finding potential biomarkers for breast cancer. The Analyst, 134, 2003–2011.
Chong, J., Wishart, D. S., & Xia, J. (2019). Using MetaboAnalyst 4.0 for comprehensive and integrative metabolomics data analysis. Current Protocols in Bioinformatics, 68, e89.
Chong, J., & Xia, J. (2020). Using MetaboAnalyst 4.0 for metabolomics data analysis, interpretation, and integration with other omics data. Computational Methods and Data Analysis for Metabolomics, 2104, 337–360.
DeFeo, E. M., Wu, C. L., McDougal, W. S., & Cheng, L. L. (2011). A decade in prostate cancer: from NMR to metabolomics. Nature Reviews Urology, 8, 301–311.
Deja, S., Porebska, I., Kowal, A., Zabek, A., Barg, W., Pawelczyk, K., Stanimirova, I., Daszykowski, M., Korzeniewska, A., Jankowska, R., & Mlynarz, P. (2014). Metabolomics provide new insights on lung cancer staging and discrimination from chronic obstructive pulmonary disease. Journal of Pharmaceutical and Biomedical Analysis, 100, 369–380.
Ferlay, J., Colombet, M., Soerjomataram, I., Parkin, D. M., Piñeros, M., Znaor, A., & Bray, F. (2021). Cancer statistics for the year 2020: An overview. International Journal of Cancer, 149, 778–789.
Garcia, E., Andrews, C., Hua, J., Kim, H. L., Sukumaran, D. K., Szyperski, T., & Odunsi, K. (2011). Diagnosis of early stage ovarian cancer by 1H NMR metabonomics of serum explored by use of a microflow NMR probe. Journal of Proteome Research, 10, 1765–1771.
Gordon, F. E., Nutt, C. L., Cheunsuchon, P., Nakayama, Y., Provencher, K. A., Rice, K. A., Zhou, Y., Zhang, X., & Klibanski, A. (2010). Increased expression of angiogenic genes in the brains of mouse meg3-null embryos. Endocrinology, 151, 2443–2452.
Gowda, G. N., & Raftery, D. (2015). Can NMR solve some significant challenges in metabolomics? Journal of Magnetic Resonance, 260, 144–160.
Gu, H., Pan, Z., Xi, B., Asiago, V., Musselman, B., & Raftery, D. (2011). Principal component directed partial least squares analysis for combining nuclear magnetic resonance and mass spectrometry data in metabolomics: Application to the detection of breast cancer. Analytica chimica acta, 686, 57–63.
Hanahan, D., & Weinberg, R. A. (2011). Hallmarks of cancer: The next generation. Cell, 144, 646–674.
Hirschhaeuser, F., Sattler, U. G., & Mueller-Klieser, W. (2011). Lactate: A metabolic key player in cancer. Cancer Research, 71, 6921–6925.
Hung, C. L., Wang, L. Y., Yu, Y. L., Chen, H. W., Srivastava, S., Petrovics, G., & Kung, H. J. (2014). A long noncoding RNA connects c-Myc to tumor metabolism. Proceedings of the National Academy of Sciences, 111, 18697–18702.
Jiang, T., Lin, Y., Yin, H., Wang, S., Sun, Q., Zhang, P., & Bi, W. (2015). Correlation analysis of urine metabolites and clinical staging in patients with ovarian cancer. International Journal of Clinical and Experimental Medicine, 8, 18165.
Jin, H., Du, W., Huang, W., Yan, J., Tang, Q., Chen, Y., & Zou, Z. (2021). lncRNA and breast cancer: Progress from identifying mechanisms to challenges and opportunities of clinical treatment. Molecular Therapy-Nucleic Acids, 25, 613–637.
Jobard, E., Pontoizeau, C., Blaise, B. J., Bachelot, T., Elena-Herrmann, B., & Trédan, O. (2014). A serum nuclear magnetic resonance-based metabolomic signature of advanced metastatic human breast cancer. Cancer Letters, 343, 33–41.
Kalyanaraman, B. (2017). Teaching the basics of cancer metabolism: developing antitumor strategies by exploiting the differences between normal and cancer cell metabolism. Redox Biology, 12, 833–842.
Kumar, U., Jain, A., Guleria, A., Misra, D. P., Goel, R., Danda, D., Misra, R., & Kumar, D. (2020). Circulatory glutamine/glucose ratio for evaluating disease activity in Takayasu arteritis: A NMR based serum metabolomics study. Journal of Pharmaceutical and Biomedical Analysis, 180, 113080.
Kumar, U., Kumar, A., Singh, S., Arya, P., Singh, S. K., Chaurasia, R. N., Singh, A., & Kumar, D. (2021). An elaborative NMR based plasma metabolomics study revealed metabolic derangements in patients with mild cognitive impairment: A study on north indian population. Metabolic Brain Disease, 36, 957–968.
Kusum, K., Raj, R., Rai, S., Pranjali, P., Ashish, A., & Vicente-Muñoz S, Chaube R, Kumar D,. (2022). Elevated circulatory proline to glutamine ratio (PQR) in endometriosis and its potential as a diagnostic biomarker. ACS Omega, 7, 14856–14866.
Lan, X., Sun, W., Dong, W., Wang, Z., Zhang, T., He, L., & Zhang, H. (2018). Downregulation of long noncoding RNA H19 contributes to the proliferation and migration of papillary thyroid carcinoma. Gene, 646, 98–105.
Li, H., Li, J., Jia, S., Wu, M., An, J., Zheng, Q., Zhang, W., & Lu, D. (2015). miR675 upregulates long noncoding RNA H19 through activating EGR1 in human liver cancer. Oncotarget, 6, 31958.
Li, Q., Cao, L., Tian, Y., Zhang, P., Ding, C., Lu, W., Jia, C., Shao, C., Liu, W., Wang, D., & Ye, H. (2018). Butyrate suppresses the proliferation of colorectal cancer cells via targeting pyruvate kinase M2 and metabolic reprogramming. Molecular & Cellular Proteomics, 17, 1531–1545.
Lin, W., Zhou, Q., Wang, C. Q., Zhu, L., Bi, C., Zhang, S., Wang, X., & Jin, H. (2020). LncRNAs regulate metabolism in cancer. International Journal of Biological Sciences, 16, 1194.
Malhotra, P., Sidhu, L., & Singh, S. (1986). Serum lactate dehydrogenase level in various malignancies. Neoplasma, 33, 641–647.
Momtazmanesh, S., & Rezaei, N. (2021). Long non-coding RNAs in diagnosis, treatment, prognosis, and progression of glioma: A state-of-the-art review. Frontiers in oncology, 11, 712786.
Nishiumi, S., Kobayashi, T., Ikeda, A., Yoshie, T., Kibi, M., Izumi, Y., Okuno, T., Hayashi, N., Kawano, S., Takenawa, T., & Azuma, T. A. (2012). A novel serum metabolomics-based diagnostic approach for colorectal cancer. PloS One, 7, e40459.
Onitilo, A. A., Engel, J. M., Greenlee, R. T., & Mukesh, B. N. (2009). Breast cancer subtypes based on ER/PR and Her2 expression: Comparison of clinicopathologic features and survival. Clinical Medicine & Research, 7, 4–13.
Parks, S. K., Mueller-Klieser, W., & Pouysségur, J. (2020). Lactate and acidity in the cancer microenvironment. Annual Review of Cancer Biology, 4, 141–158.
Patti, G. J., Yanes, O., & Siuzdak, G. (2012). Metabolomics: The apogee of the omics trilogy. Nature Reviews Molecular Cell Biology, 13, 263–269.
Putluri, N., Shojaie, A., Vasu, V. T., Vareed, S. K., Nalluri, S., Putluri, V., Thangjam, G. S., Panzitt, K., Tallman, C. T., Butler, C., & Sana, T. R. (2011). Metabolomic profiling reveals potential markers and bioprocesses altered in bladder cancer progression. Cancer Research, 71, 7376–7386.
Racker, E. (1972). Bioenergetics and the problem of tumor growth: An understanding of the mechanism of the generation and control of biological energy may shed light on the problem of tumor growth. American Scientist, 60, 56–63.
Reis-Mendes, A., Carvalho, F., Remião, F., Sousa, E., Bastos, M. L., & Costa, V. M. (2019). The main metabolites of fluorouracil + adriamycin + cyclophosphamide (FAC) are not major contributors to FAC toxicity in H9c2 cardiac differentiated cells. Biomolecules, 9, 98.
Rodic, S., & Vincent, M. D. (2018). Reactive oxygen species (ROS) are a key determinant of cancer’s metabolic phenotype. International Journal of Cancer, 142, 440–448.
Salani, B., Ravera, S., Amaro, A., Salis, A., Passalacqua, M., Millo, E., Damonte, G., Marini, C., Pfeffer, U., Sambuceti, G., & Cordera, R. (2015). IGF1 regulates PKM2 function through akt phosphorylation. Cell Cycle, 14, 1559–1567.
Schmittgen, T. D., & Livak, K. J. (2008). Analyzing real-time PCR data by the comparative CT method. Nature Protocols, 3, 1101–1108.
Singh, A., Prakash, V., Gupta, N., Kumar, A., Kant, R., & Kumar, D. (2022). Serum metabolic disturbances in lung cancer investigated through an elaborative NMR-based serum metabolomics approach. ACS Omega, 7, 5510–5520.
Sreekumar, A., Poisson, L. M., Rajendiran, T. M., Khan, A. P., Cao, Q., Yu, J., Laxman, B., Mehra, R., Lonigro, R. J., Li, Y., & Nyati, M. K. (2009). Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature, 457, 910–914.
Tenori, L., Oakman, C., Claudino, W. M., Bernini, P., Cappadona, S., Nepi, S., Biganzoli, L., Arbushites, M. C., Luchinat, C., Bertini, I., & Di Leo, A. (2012). Exploration of serum metabolomic profiles and outcomes in women with metastatic breast cancer: A pilot study. Molecular Oncology, 6, 437–444.
Waks, A. G., & Winer, E. P. (2019). Breast cancer treatment: A review. JAMA, 321, 288–300.
Walenta, S., Wetterling, M., Lehrke, M., Schwickert, G., Sundfør, K., Rofstad, E. K., & Mueller-Klieser, W. (2000). High lactate levels predict likelihood of metastases, tumor recurrence, and restricted patient survival in human cervical cancers. Cancer Research, 60, 916–921.
Wang, X., Zhang, H., & Chen, X. (2019). Drug resistance and combating drug resistance in cancer. Cancer Drug Resistance (Alhambra Calif), 2, 141.
Wang, Y., Wu, P., Lin, R., Rong, L., Xue, Y., & Fang, Y. (2015). LncRNA NALT interaction with NOTCH1 promoted cell proliferation in pediatric T cell acute lymphoblastic leukemia. Scientific Reports, 5, 1–10.
Wang, Y., & Zhou, B. P. (2011). Epithelial-mesenchymal transition in breast cancer progression and metastasis. Chinese Journal of Cancer, 30, 603.
Wang, Y., Zhou, P., Li, P., Yang, F., & Gao, X. (2020). Long non-coding RNA H19 regulates proliferation and doxorubicin resistance in MCF-7 cells by targeting PARP1. Bioengineered, 11, 536–546.
Warburg, O., Wind, F., & Negelein, E. (1927). Killing-off of tumor cells in vitro. Journal of General Physiology, 8, 519–530.
Ward, P. S., & Thompson, C. B. (2012). Metabolic reprogramming: A cancer hallmark even warburg did not anticipate. Cancer Cell, 21, 297–308.
Weigelt, B., & Reis-Filho, J. S. (2010). Molecular profiling currently offers no more than tumour morphology and basic immunohistochemistry. Breast Cancer Research, 12, 1–4.
Woo, H. M., Kim, K. M., Choi, M. H., Jung, B. H., Lee, J., Kong, G., Nam, S. J., Kim, S., Bai, S. W., & Chung, B. C. (2009). Mass spectrometry based metabolomic approaches in urinary biomarker study of women’s cancers. Clinica chimica acta, 400, 63–69.
Zaal, E. A., & Berkers, C. R. (2018). The influence of metabolism on drug response in cancer. Frontiers in Oncology, 8, 500.